DrugPatentWatch Database Preview
Hyaluronidase - Biologic Drug Details
Email this page to a colleague
» See Plans and PricingSummary for hyaluronidase
| Tradenames: | 3 |
| Patents: | 483 |
| Applicants: | 3 |
| BLAs: | 3 |
| Suppliers: see list | 2 |
| Recent Clinical Trials: | See clinical trials for hyaluronidase |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for hyaluronidase |
Recent Clinical Trials for hyaluronidase
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Wisconsin, Madison | Phase 4 |
| Regeneron Pharmaceuticals | Phase 2 |
| Massachusetts Eye and Ear Infirmary | Phase 2 |
Recent Litigation for hyaluronidase
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| KYTHERA BIOPHARMACEUTICALS, INC. v. SLAYBACK PHARMA LLC | 2018-11-09 |
| Halozyme, Inc. v. Lee | 2016-12-19 |
| PIECZENIK v. BAYER CORPORATION | 2010-05-04 |
See all hyaluronidase litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| 2017-05-30 | |
| 2017-01-31 |
Company Disclosures: US Patents for hyaluronidase
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therap | HYLENEX RECOMBINANT | hyaluronidase recombinant human | INJECTABLE;INJECTION | 021859 | 001 | 2005-12-02 | Start Trial | Halozyme, Inc. (San Diego, CA) | 2039-09-22 | RX | company | |
| Halozyme Therap | HYLENEX RECOMBINANT | hyaluronidase recombinant human | INJECTABLE;INJECTION | 021859 | 001 | 2005-12-02 | Start Trial | Halozyme, Inc. (San Diego, CA) | 2023-03-05 | RX | company | |
| Halozyme Therap | HYLENEX RECOMBINANT | hyaluronidase recombinant human | INJECTABLE;INJECTION | 021859 | 001 | 2005-12-02 | Start Trial | Halozyme, Inc. (San Diego, CA) | 2023-03-05 | RX | company | |
| Halozyme Therap | HYLENEX RECOMBINANT | hyaluronidase recombinant human | INJECTABLE;INJECTION | 021859 | 001 | 2005-12-02 | Start Trial | Halozyme, Inc. (San Diego, CA) | 2023-03-05 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for hyaluronidase
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharm | AMPHADASE | hyaluronidase | INJECTABLE;INJECTION | 021665 | 001 | 2005-11-03 | Start Trial | Oxyrane UK Limited (Manchester, GB) | 2030-09-29 | RX | search | |
| Amphastar Pharm | AMPHADASE | hyaluronidase | INJECTABLE;INJECTION | 021665 | 001 | 2005-11-03 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amphastar Pharm | AMPHADASE | hyaluronidase | INJECTABLE;INJECTION | 021665 | 001 | 2005-11-03 | Start Trial | Halozyme, Inc. (San Diego, CA) | 2023-03-05 | RX | search | |
| Amphastar Pharm | AMPHADASE | hyaluronidase | INJECTABLE;INJECTION | 021665 | 001 | 2005-11-03 | Start Trial | Oxyrane UK Limited (Manchester, GB) VIB vzw (Ghent, BE) Universiteit Gent (Ghent, BE) | 2027-04-03 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for hyaluronidase
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2007143451 | Start Trial |
| Australia | 1973197 | Start Trial |
| Canada | 2264484 | Start Trial |
| Japan | 4125234 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for hyaluronidase
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2013 028 | Romania | Start Trial | PRODUCT NAME: MICROPLASMINA; NATIONAL AUTHORISATION NUMBER: EU/1/13/819/001; DATE OF NATIONAL AUTHORISATION: 20130313; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/819/001; DATE OF FIRST AUTHORISATION IN EEA: 20130313 |
| 2013020 | Lithuania | Start Trial | PRODUCT NAME: OCRIPLASMINUM (MICROPLASMINUM); REGISTRATION NO/DATE: EU/1/13/819/001 20130313 |
| 2013000076 | Germany | Start Trial | PRODUCT NAME: MIKROPLASMIN; REGISTRATION NO/DATE: EU/1/13/819/001 20130313 |
| C/GB13/057 | United Kingdom | Start Trial | PRODUCT NAME: OCRIPLASMIN; REGISTERED: UK EU/1/13/819/001 20130315 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
